Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
33 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
2Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Managing Member of Baker Bros. Advisors LP, a biotechnology-focused investment advisor founded in 2000. Serves on boards of Incyte, Acadia Pharmaceuticals, and Prelude Therapeutics. Previously portfolio manager at Tisch Financial Management and private equity investor at Credit Suisse First Boston.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Chair

Incyte (NASDAQ: INCY)

Jan 1, 2001 – Present

Independence: Not independent

Source effective: 2026-04-28 · Observed: 2026-04-28T22:20:09.131+00:00

confirmedView source

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

MADRIGAL PHARMACEUTICALS, INC.

2023-01-01 · current

Confirmed by public sourceView source

Chair

Incyte

2001-01-01 · current

Confirmed by public sourceView source

Director

Prelude Therapeutics Inc

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Incyte

Open Incyte profile →

Chair at Incyte

2001-01-01 → End not stated

current · source reported

Observed: 2026-09-25

IncyteIncyteMADRIGAL PHARMACEU…MADRIGAL PHARMACEUTICALS, INC.Prelude Therapeuti…Prelude Therapeutics IncJulian C. Baker

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingIncyte Corporation director board sourceSupports Board membership, Committee assignments, Director since, Board independence.Open sourceSource 2 · Sec FilingPAYS DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 3 · Sec FilingMYE 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 4 · Sec FilingPIPR 10-K executive officersSupports Executive company, Executive title.Open sourceSource 5 · Sec FilingMDGL DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open sourceSource 6 · Sec FilingPRLD DEF 14A director slateSupports Board role, Committee assignments.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:julian-c-baker
Record version
public-0

Published evidence records

14 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Incyte Corporation director board source

    sec filing · Source published: Apr 28, 2026 · Retrieved: May 3, 2026

    Supports 5 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Incyte Corporation · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Madrigal Pharmaceuticals · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Prelude Therapeutics Inc · Claim reviewed: May 3, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026

  2. INCY DEF 14A director slate

    sec filing · Source published: Apr 28, 2026 · Retrieved: Apr 28, 2026

    Supports 2 claims
    • Board role: Board role: Chair · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Nominating/Governance, Compensation · Claim reviewed: May 16, 2026

  3. Open source

    sec proxy · Source published: Apr 28, 2026 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Chair at Incyte · Claim reviewed: May 16, 2026

  4. PAYS DEF 14A executive officers

    sec filing · Source published: Mar 26, 2026 · Retrieved: May 5, 2026

    Supports 2 claims
    • Executive company: Executive at Paysign, Inc. · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Named Executive Officer (Non-PEO NEO) · Claim reviewed: May 5, 2026

  5. MYE 10-K executive officers

    sec filing · Source published: Mar 5, 2026 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at MYERS INDUSTRIES INC · Claim reviewed: May 15, 2026
    • Executive title: Executive title: President, Distribution Segment · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  6. PIPR 10-K executive officers

    sec filing · Source published: Feb 26, 2026 · Retrieved: May 5, 2026

    Supports 2 claims
    • Executive company: Executive at PIPER SANDLER COMPANIES · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Global Co-Head of Investment Banking and Capital Markets · Claim reviewed: May 5, 2026

  7. MDGL DEF 14A director slate

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 16, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Chair · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Nominating/Governance · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Baker Bros. Advisors LP · Claim reviewed: May 1, 2026
    • Executive title: Executive title: Managing Member · Claim reviewed: May 1, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  8. Madrigal Pharmaceuticals director board source

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 3, 2026

    Supports 5 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Incyte Corporation · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Madrigal Pharmaceuticals · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Prelude Therapeutics Inc · Claim reviewed: May 3, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026

  9. PRLD DEF 14A director slate

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 16, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Nominating/Governance, Compensation · Claim reviewed: May 16, 2026

  10. Open source

    sec proxy · Source published: Apr 29, 2025 · Retrieved: May 1, 2026

    Supports 1 claim
    • Professional Role: Director at MADRIGAL PHARMACEUTICALS, INC. · Claim reviewed: May 16, 2026

  11. Open source

    sec proxy · Source published: Apr 29, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Prelude Therapeutics Inc · Claim reviewed: May 16, 2026

  12. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Madrigal Pharmaceuticals · Claim reviewed: May 3, 2026

  13. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Incyte Corporation · Claim reviewed: May 3, 2026

  14. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Prelude Therapeutics Inc · Claim reviewed: May 3, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board independence · CorroboratedIndependent directorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · CorroboratedServes on the board of Incyte CorporationSupported by 4 public records3 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board membership · CorroboratedServes on the board of Madrigal PharmaceuticalsSupported by 4 public records3 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board membership · CorroboratedServes on the board of Prelude Therapeutics IncSupported by 3 public records3 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board role · CorroboratedBoard role: ChairSupported by 2 public records2 sources
Verification
Corroborated
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 28, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · CorroboratedNo committee assignment disclosed in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Committee assignments · CorroboratedCommittee assignments: Nominating/Governance, CompensationSupported by 2 public records2 sources
Verification
Corroborated
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 28, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Baker Bros. Advisors LP1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 1, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at MYERS INDUSTRIES INC1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at Paysign, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive company · Source reportedExecutive at PIPER SANDLER COMPANIES1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: Global Co-Head of Investment Banking and Capital Markets1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: Managing Member1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 1, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Named Executive Officer (Non-PEO NEO)1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: President, Distribution Segment1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources14 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Director since · Board independence

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 28, 2026

    Supports: Board role · Committee assignments

  3. https://www.sec.gov/Archives/edgar/data/879169/000087916926000031/incy-20260428.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Chair at Incyte (NASDAQ: INCY)

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

    Supports: Executive company · Executive title

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

    Supports: Executive company · Executive title

  7. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  8. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Director since · Board independence

  9. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Board role · Committee assignments

  10. https://www.sec.gov/Archives/edgar/data/1157601/000110465925041254/tm2512589-3_def14a.htm

    Sec Proxy · Tier not stated · Reviewed May 1, 2026

    Supports: Director at MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL)

  11. https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at Prelude Therapeutics Inc (NASDAQ: PRLD)

  12. https://www.sec.gov/Archives/edgar/data/1157601/000110465925041254/tm2512589-3_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  13. https://www.sec.gov/Archives/edgar/data/879169/000087916926000031/incy-20260428.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  14. https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership